Compare BBY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBY | RPRX |
|---|---|---|
| Founded | 1966 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 16.2B |
| IPO Year | N/A | 2020 |
| Metric | BBY | RPRX |
|---|---|---|
| Price | $74.02 | $39.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 3 |
| Target Price | ★ $84.24 | $46.00 |
| AVG Volume (30 Days) | 4.1M | ★ 4.3M |
| Earning Date | 11-25-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.12% | 2.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.02 | 1.75 |
| Revenue | ★ $41,825,000,000.00 | $2,349,844,000.00 |
| Revenue This Year | $1.77 | $37.13 |
| Revenue Next Year | $1.32 | $1.48 |
| P/E Ratio | $24.54 | ★ $22.68 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $54.99 | $24.05 |
| 52 Week High | $91.68 | $41.24 |
| Indicator | BBY | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 57.50 |
| Support Level | $74.24 | $39.24 |
| Resistance Level | $83.67 | $40.50 |
| Average True Range (ATR) | 2.59 | 0.91 |
| MACD | -0.30 | -0.08 |
| Stochastic Oscillator | 11.07 | 76.02 |
With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.